Why Ageing Makes Cancer More Dangerous-And How Tumors Hijack Cellular Stress Pathways to Spread

A growing body of evidence suggests that ageing does far more than increase the risk of developing cancer. It fundamentally changes the biology of the disease itself. A major new study published in Nature now provides compelling mechanistic evidence that ageing actively reprograms lung cancer into a more metastatic and lethal disease state through chronic activation of the integrated stress response (ISR), a conserved cellular adaptation pathway designed to help cells survive hostile environments.

The findings challenge long-standing assumptions in oncology. For decades, cancer progression has largely been viewed through the lens of uncontrolled Tumor growth. However, the new data suggest that in older individuals, tumor cells may actually sacrifice rapid growth in exchange for something far more dangerous: enhanced metastatic competence. In other words, ageing appears to shift Tumors away from expansion at the primary site and toward dissemination throughout the body.

This distinction is critical because metastasis, not the primary tumor itself, accounts for approximately 90% of cancer-related deaths.

The Disconnect Between Cancer Research and Cancer Patients

Lung cancer is predominantly a disease of older adults. The median age at diagnosis is approximately 70 years, with incidence peaking between 65 and 75 years of age. Yet despite this clinical reality, the overwhelming majority of mechanistic cancer studies continue to rely on young animal models. Most genetically engineered mouse models used in oncology research employ mice equivalent to young adulthood in humans, failing to capture the molecular and physiological environment present in elderly patients.

This disconnect may not be trivial. It may represent one of the reasons why numerous therapies that demonstrate impressive efficacy in preclinical studies ultimately fail in clinical trials.

To directly address this issue, investigators at the University of Gothenburg and collaborating institutions compared KRAS-driven lung adenocarcinoma progression in young mice and physiologically aged mice. The aged animals closely mirrored the age range of human patients typically diagnosed with non-small cell lung cancer (NSCLC). The results revealed a striking paradox.

Smaller Tumors, More Aggressive Disease

Contrary to expectations, aged mice developed significantly smaller primary lung tumors than younger mice. Tumor burden was reduced by approximately 2.5-fold in old animals. Histological analyses further demonstrated that tumors in aged mice were fewer in number, smaller in size, and less proliferative.

At first glance, these findings might appear beneficial. However, the opposite proved true.

Despite smaller primary tumors, aged mice exhibited dramatically increased metastatic dissemination. Cancer spread more frequently to lymph nodes and distant organs including the kidneys, heart, liver, lungs, and brain. Survival was significantly shortened in the older animals. The disease progressed more aggressively even though the primary tumor mass itself was reduced.

This observation fundamentally alters how ageing and cancer progression are viewed. The data suggest that ageing does not simply accelerate tumor growth. Instead, ageing reshapes tumor evolution into a state optimized for invasion, dissemination, and survival during metastatic spread.

Ageing Reprograms Tumor Cell Identity

To understand why tumors from older mice became highly metastatic, researchers isolated tumor cells from young and old animals and subjected them to extensive molecular and functional analyses.

The tumor cells derived from aged mice did not proliferate faster than those from young mice, consistent with the smaller tumor burden observed in vivo. However, they exhibited multiple hallmarks of metastatic transformation. These included increased epithelial-to-mesenchymal transition (EMT), enhanced resistance to anoikis, greater invasive behavior in extracellular matrices, and increased ability to survive under detached three-dimensional growth conditions.

Anoikis resistance is particularly important during metastasis because tumor cells must survive after detaching from their original tissue and entering circulation. Normally, detached epithelial cells undergo programmed cell death. Metastatic cells bypass this safeguard.

When transplanted into recipient animals, tumor cells from aged mice seeded distant organs with remarkable efficiency, colonizing lungs, liver, kidneys, heart, and brain at rates that young tumor cells could not achieve.

The data clearly indicated that physiological ageing intrinsically alters tumor cell state.

The Integrated Stress Response Becomes Chronically Activated

To uncover the mechanisms driving this transformation, investigators performed RNA sequencing and chromatin accessibility analyses using ATAC-seq.

Two dominant biological programs emerged repeatedly from the analyses:

  • Epithelial-to-mesenchymal transition (EMT)
  • Activation of the unfolded protein response (UPR) and integrated stress response (ISR)

 
The ISR is a highly conserved cellular adaptation pathway that becomes activated during stress conditions such as nutrient deprivation, hypoxia, viral infection, oxidative damage, and accumulation of misfolded proteins within the endoplasmic reticulum. Under normal conditions, the ISR functions as a temporary survival mechanism that helps cells restore homeostasis.

In aged tumor cells, however, this pathway became chronically activated.

The investigators discovered that tumor cells from old mice displayed heightened sensitivity to activation of the PERK–eIF2α branch of the unfolded protein response, resulting in sustained signaling through the transcription factor ATF4.

Importantly, this was not merely transient stress signaling. Epigenetic alterations associated with ageing had fundamentally rewired the system.

Epigenetic Changes Lock the Stress Response in the “On” Position

Chromatin accessibility studies revealed increased accessibility at the Atf4 gene locus itself, making the gene more transcriptionally active and easier to induce during stress. Simultaneously, several genes responsible for resolving or terminating stress responses became epigenetically repressed.

Among the affected genes was GADD34, a key negative regulator that normally shuts down ISR signaling by dephosphorylating eIF2α after stress resolution.

In aged tumor cells, the chromatin surrounding these stress-resolution genes became less accessible, impairing their activation. The result was persistent ISR activation and sustained production of ATF4.

In essence, ageing had rewired the epigenetic architecture of tumor cells in a way that permanently sensitized them to stress adaptation.

ATF4 Becomes the Central Driver of Metastasis

ATF4 emerged as the dominant molecular regulator linking ageing to metastatic progression.

Tumors from aged mice showed markedly higher numbers of ATF4-positive nuclei than tumors from young animals. When researchers pharmacologically inhibited ISR signaling using ISRIB, ATF4 levels fell sharply and metastatic properties were suppressed. Similarly, genetic deletion or knockdown of ATF4 significantly reduced anoikis resistance and metastatic colonization.

The most striking experiments involved forced ATF4 overexpression.

When ATF4 was artificially overexpressed in tumor cells derived from young mice, those cells rapidly acquired metastatic characteristics resembling aged tumor cells. EMT markers increased, invasive behavior intensified, and metastatic dissemination dramatically rose. Human A549 lung adenocarcinoma cells engineered to overexpress ATF4 also became highly metastatic in vivo, including spread to extrapulmonary organs such as the heart.

These findings established that ATF4 is not simply correlated with metastatic disease. It is both necessary and sufficient to drive it.

Ageing Also Rewires Tumor Metabolism

Beyond its effects on cell identity and invasion, ATF4 profoundly altered tumor metabolism.

Stable isotope tracing experiments demonstrated that aged tumor cells shifted away from glucose-driven anaplerosis and became heavily dependent on glutamine metabolism to replenish tricarboxylic acid (TCA) cycle intermediates.

This metabolic shift was directly controlled by ATF4. Removing ATF4 reduced glutamine utilization, whereas overexpressing ATF4 enhanced glutamine-driven metabolic flux.

The findings suggest that ageing-induced stress signaling creates a metabolically rewired tumor state optimized for metastatic survival.

A Potential Therapeutic Vulnerability

Perhaps the most clinically significant finding from the study is that this ageing-associated metabolic state appears therapeutically targetable.

Because aged metastatic tumor cells became highly dependent on glutamine metabolism, they showed remarkable sensitivity to glutaminase inhibition. Treatment with CB-839 (telaglenastat), a glutaminase inhibitor, almost completely suppressed metastatic dissemination in aged tumor models.

Importantly, the drug did not significantly reduce primary tumor growth. Instead, its effects were highly selective for metastasis.

This distinction is extremely important because many anti-cancer therapies successfully shrink primary tumors yet fail to meaningfully improve survival due to persistent metastatic progression.

The glutamine dependency itself was ATF4-dependent. Suppressing ATF4 eliminated sensitivity to CB-839, while inducing ATF4 in previously resistant young tumor cells created new glutaminase inhibitor sensitivity.

These observations suggest that ageing-induced metabolic plasticity may represent a druggable vulnerability specifically within metastatic disease.

Human Lung Cancer Patients Mirror the Mouse Findings

To determine whether these observations were clinically relevant, the investigators analyzed nearly 1,000 NSCLC patients diagnosed in western Sweden between 2016 and 2018.

Older patients harboring KRAS-mutant tumors were significantly more likely to present with advanced metastatic disease despite having smaller primary tumors, closely mirroring the mouse model observations.

High ATF4 expression was also strongly associated with poor survival in advanced-stage lung adenocarcinoma. Patients with elevated ATF4 levels had dramatically reduced five-year and eight-year survival rates compared with patients exhibiting low ATF4 expression.

Notably, younger patients whose tumors expressed high levels of ATF4 behaved clinically more like older patients, suggesting that ATF4 may function as a biological readout of tumor ageing rather than chronological age alone.

Implications for Cancer Research and Therapy

The implications of this work extend well beyond lung cancer biology.

The study strongly suggests that ageing is not merely a demographic variable in oncology. It is a biological modifier capable of fundamentally reshaping tumor evolution through epigenetic stress adaptation pathways.

This has several major consequences:

  • Experimental cancer models using exclusively young animals may fail to accurately represent human disease biology.
  • Metastatic progression may be driven by stress-adaptive programs rather than solely by uncontrolled proliferation.
  • Therapies targeting ISR signaling or glutamine metabolism may be particularly effective in elderly patients with ATF4-high tumors.
  • Biomarkers such as ATF4 expression could potentially help identify patients at greatest risk for aggressive metastatic disease.

 
Perhaps most importantly, the study reframes metastasis itself as a stress-adaptation phenotype driven by ageing-associated epigenetic remodeling.

Rather than simply growing faster, aged tumors appear to evolve into more resilient, stress-adapted, migratory systems optimized for survival during dissemination.

That transformation may explain why cancer becomes dramatically more lethal with age.

Reference

Patel, A.A.H., Dzanan, J.J., Ali, K.X. et al. Ageing promotes metastasis via activation of the integrated stress response. Nature 652, 1339–1348 (2026). https://doi.org/10.1038/s41586-026-10216-0

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)